DE69718612T2 - Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung - Google Patents
Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendungInfo
- Publication number
- DE69718612T2 DE69718612T2 DE69718612T DE69718612T DE69718612T2 DE 69718612 T2 DE69718612 T2 DE 69718612T2 DE 69718612 T DE69718612 T DE 69718612T DE 69718612 T DE69718612 T DE 69718612T DE 69718612 T2 DE69718612 T2 DE 69718612T2
- Authority
- DE
- Germany
- Prior art keywords
- recombinant viruses
- infectious recombinant
- aqueous solution
- viruses according
- preserving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 78
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 51
- 230000002458 infectious effect Effects 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000003612 virological effect Effects 0.000 title claims abstract description 28
- 239000007900 aqueous suspension Substances 0.000 title claims description 20
- 238000004321 preservation Methods 0.000 title claims description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 48
- 229930006000 Sucrose Natural products 0.000 claims abstract description 48
- 239000005720 sucrose Substances 0.000 claims abstract description 48
- 239000007864 aqueous solution Substances 0.000 claims abstract description 31
- 239000000243 solution Substances 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 63
- 235000011147 magnesium chloride Nutrition 0.000 claims description 31
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 25
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000872 buffer Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 14
- 229920000053 polysorbate 80 Polymers 0.000 claims description 14
- 241000701161 unidentified adenovirus Species 0.000 claims description 11
- 239000011780 sodium chloride Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 6
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 3
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 3
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 3
- YNLCVAQJIKOXER-UHFFFAOYSA-N N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid Chemical compound OCC(CO)(CO)NCCCS(O)(=O)=O YNLCVAQJIKOXER-UHFFFAOYSA-N 0.000 claims description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 3
- 239000007997 Tricine buffer Substances 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000007998 bicine buffer Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 235000011148 calcium chloride Nutrition 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 3
- 239000011565 manganese chloride Substances 0.000 claims description 3
- 235000002867 manganese chloride Nutrition 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 abstract description 10
- 238000001415 gene therapy Methods 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000007983 Tris buffer Substances 0.000 description 11
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 8
- 101100422771 Caenorhabditis elegans sup-9 gene Proteins 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 239000012537 formulation buffer Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- -1 NaCl or KCl Chemical class 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9608851A FR2751343B1 (fr) | 1996-07-16 | 1996-07-16 | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| PCT/FR1997/001308 WO1998002522A1 (fr) | 1996-07-16 | 1997-07-15 | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69718612D1 DE69718612D1 (de) | 2003-02-27 |
| DE69718612T2 true DE69718612T2 (de) | 2003-11-06 |
Family
ID=9494078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69718612T Expired - Lifetime DE69718612T2 (de) | 1996-07-16 | 1997-07-15 | Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6451256B1 (enExample) |
| EP (1) | EP0853660B1 (enExample) |
| JP (1) | JP3681401B2 (enExample) |
| AT (1) | ATE231549T1 (enExample) |
| AU (1) | AU711409B2 (enExample) |
| CA (1) | CA2232604C (enExample) |
| DE (1) | DE69718612T2 (enExample) |
| DK (1) | DK0853660T3 (enExample) |
| ES (1) | ES2187798T3 (enExample) |
| FR (1) | FR2751343B1 (enExample) |
| WO (1) | WO1998002522A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US20080261289A1 (en) * | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
| ES2185417T3 (es) * | 1998-12-03 | 2003-04-16 | Avigen Inc | Excipientes para usar en formulaciones farmaceuticas de virus adeno-asociados, y formulaciones farmaceuticas producidas con ellos. |
| US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| US6225289B1 (en) * | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| FR2791999B1 (fr) * | 1999-04-09 | 2001-09-07 | Aventis Pharma Sa | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| CA2364562A1 (fr) * | 1999-04-09 | 2000-10-19 | Aventis Pharma S.A. | Composition destinee a la conservation d'adenovirus recombinants infectieux |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| CA2399321C (en) | 2000-03-07 | 2013-04-30 | Robert K. Evans | Adenovirus formulations |
| WO2001085928A1 (en) * | 2000-05-10 | 2001-11-15 | Mitsubishi Pharma Corporation | Method of preparing virus vector |
| CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| JP2005515245A (ja) * | 2002-01-18 | 2005-05-26 | シエーリング アクチエンゲゼルシャフト | アデノウィルスの安定化された配合物 |
| KR100507794B1 (ko) * | 2003-02-11 | 2005-08-17 | 한미약품 주식회사 | 고농도 레트로 바이러스 현탁액 제조 방법 |
| US20070148765A1 (en) * | 2003-11-19 | 2007-06-28 | Evans Robert K | Preservative-containing virus formulations |
| CN101343625A (zh) * | 2004-02-23 | 2009-01-14 | 克鲁塞尔荷兰公司 | 病毒纯化方法 |
| GB0502661D0 (en) * | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| ES2317517T5 (es) * | 2005-04-11 | 2016-01-21 | Crucell Holland B.V. | Purificación de virus usando ultrafiltración |
| CN1961961B (zh) * | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| AU2009319254B2 (en) | 2008-11-03 | 2015-04-30 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
| MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
| SG190418A1 (en) | 2010-12-02 | 2013-07-31 | Oncolytics Biotech Inc | Liquid viral formulations |
| ES2630012T3 (es) | 2010-12-02 | 2017-08-17 | Oncolytics Biotech Inc. | Formulaciones virales liofilizadas |
| AU2013231423B2 (en) | 2012-03-12 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
| AU2013237424B2 (en) | 2012-03-22 | 2017-07-06 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
| CN104640564B (zh) | 2012-07-10 | 2020-08-04 | 特兰斯吉恩股份有限公司 | 分枝杆菌抗原疫苗 |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| US10899800B2 (en) | 2013-04-25 | 2021-01-26 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| BR112015031509B1 (pt) | 2013-06-17 | 2023-05-09 | Janssen Vaccines & Prevention B.V. | Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende |
| RU2695462C2 (ru) | 2014-01-09 | 2019-07-23 | Трансген Са | Гибридизация гетероолигомерных микобактериальных антигенов |
| US9721484B2 (en) | 2014-06-23 | 2017-08-01 | Humanetics Innovative Solutions, Inc. | Shoulder kit assembly for crash test dummy |
| EP3169341B1 (en) | 2014-07-16 | 2019-06-05 | Transgene SA | Oncolytic virus for expression of immune checkpoint modulators |
| US10008130B2 (en) | 2014-09-17 | 2018-06-26 | Humanetics Innovative Solutions, Inc. | Omni-directional shoulder assembly for crash test dummy |
| CA2975432A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| AU2016249798B2 (en) | 2015-04-14 | 2022-05-26 | Janssen Vaccines And Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| BR112017027448A2 (pt) | 2015-07-07 | 2018-09-04 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
| WO2017005848A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| EA201892250A1 (ru) | 2016-04-05 | 2019-03-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| EA039095B1 (ru) | 2016-04-05 | 2021-12-03 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные растворимые f-белки rsv до слияния |
| JP7046835B2 (ja) | 2016-05-12 | 2022-04-04 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 強力でバランスのとれた双方向性プロモーター |
| CN109311946A (zh) | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| JP6683847B2 (ja) | 2016-06-20 | 2020-04-22 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 強力でバランスのとれた双方向性プロモーター |
| WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| TW201825511A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現免疫檢查點調節子的溶瘤病毒 |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| BR112019015671A2 (pt) | 2017-02-09 | 2020-04-14 | Janssen Vaccines & Prevention Bv | promotor potente e curto para expressão de genes heterológicos |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| CN111163800A (zh) | 2017-09-15 | 2020-05-15 | 扬森疫苗与预防公司 | 用于安全诱导针对rsv的免疫的方法 |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3875119A4 (en) | 2018-10-30 | 2022-08-31 | The University of Tokyo | ONCOLYTIC VIRUS FOR CANCER THERAPY |
| CR20210306A (es) | 2018-11-13 | 2021-07-22 | Janssen Vaccines & Prevention Bv | Proteínas f de prefusión del vrs estabilizadas |
| EP4097122A4 (en) | 2020-01-31 | 2024-07-17 | Beth Israel Deaconess Medical Center, Inc. | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES |
| CA3168761A1 (en) | 2020-03-19 | 2021-09-23 | Minna HASSINEN | Temperature-responsive virus storage system |
| CN116322740A (zh) | 2020-07-13 | 2023-06-23 | 特兰斯吉恩股份有限公司 | 免疫抑制的治疗 |
| WO2022161502A1 (zh) | 2021-02-01 | 2022-08-04 | 羿尊生物医药（浙江）有限公司 | 一种靶向蛋白降解系统及其应用 |
| KR20230147156A (ko) | 2021-02-19 | 2023-10-20 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합 전 rsv fb 항원 |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| JP2025523573A (ja) | 2022-07-01 | 2025-07-23 | トランジェーヌ | サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質 |
| EP4573113A1 (en) | 2022-08-18 | 2025-06-25 | Transgene | Chimeric poxviruses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2668064B1 (fr) * | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5658779A (en) * | 1992-03-20 | 1997-08-19 | Ligochem, Inc. | Method of adsorbing viruses from fluid compositions |
| AU7971194A (en) * | 1993-10-12 | 1995-05-04 | Chiron Corporation | Methods for preserving recombinant viruses |
| FR2711523B1 (fr) * | 1993-10-26 | 1996-02-16 | Transgene Sa | Procédé de préparation d'un aérosol viral. |
| US5545555A (en) * | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| US5932223A (en) * | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
-
1996
- 1996-07-16 FR FR9608851A patent/FR2751343B1/fr not_active Expired - Fee Related
-
1997
- 1997-07-15 CA CA002232604A patent/CA2232604C/fr not_active Expired - Lifetime
- 1997-07-15 AT AT97933740T patent/ATE231549T1/de active
- 1997-07-15 DK DK97933740T patent/DK0853660T3/da active
- 1997-07-15 AU AU36986/97A patent/AU711409B2/en not_active Expired
- 1997-07-15 WO PCT/FR1997/001308 patent/WO1998002522A1/fr not_active Ceased
- 1997-07-15 JP JP50569198A patent/JP3681401B2/ja not_active Expired - Lifetime
- 1997-07-15 US US09/043,187 patent/US6451256B1/en not_active Expired - Lifetime
- 1997-07-15 ES ES97933740T patent/ES2187798T3/es not_active Expired - Lifetime
- 1997-07-15 DE DE69718612T patent/DE69718612T2/de not_active Expired - Lifetime
- 1997-07-15 EP EP97933740A patent/EP0853660B1/fr not_active Expired - Lifetime
-
2002
- 2002-08-15 US US10/218,564 patent/US20030082206A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998002522A1 (fr) | 1998-01-22 |
| ATE231549T1 (de) | 2003-02-15 |
| AU3698697A (en) | 1998-02-09 |
| EP0853660B1 (fr) | 2003-01-22 |
| CA2232604C (fr) | 2005-06-28 |
| EP0853660A1 (fr) | 1998-07-22 |
| FR2751343A1 (fr) | 1998-01-23 |
| AU711409B2 (en) | 1999-10-14 |
| ES2187798T3 (es) | 2003-06-16 |
| CA2232604A1 (fr) | 1998-01-22 |
| US20030082206A1 (en) | 2003-05-01 |
| DE69718612D1 (de) | 2003-02-27 |
| JP2000500026A (ja) | 2000-01-11 |
| FR2751343B1 (fr) | 1998-12-18 |
| DK0853660T3 (da) | 2003-05-05 |
| JP3681401B2 (ja) | 2005-08-10 |
| US6451256B1 (en) | 2002-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69718612T2 (de) | Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung | |
| DE69429260T3 (de) | Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie | |
| DE69535684T2 (de) | Zusammensetzungen welche DNA zerstoerende Agentien und P53 enthalten | |
| DE69331526T2 (de) | Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel | |
| DE69534902T2 (de) | Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen | |
| DE69434781T2 (de) | Defektive rekombinante adenoviren zur tumor-gentherapie | |
| DE69518910T4 (de) | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle | |
| US6740320B1 (en) | Recombinant P53 adenovirus methods and compositions | |
| DE69827021T2 (de) | An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese | |
| DE69938255T2 (de) | Verfahren und zusammensetzung zur konservierung von adenoviren | |
| DE69931376T2 (de) | Häm-oxygenase 1 zur hemmung der glatten muskelzellenmigration | |
| DE69215355T2 (de) | Stabilisierter Varizella-Lebendimpfstoff | |
| DE69425989T2 (de) | Neue Komplementations-Zelllinien für defekte adenovirale Vektoren | |
| DE60035124T2 (de) | Ein oncolytisches adenovirus | |
| DE69534791T2 (de) | Vektoren zur gewebsspezifischen replikation | |
| DE69738640T2 (de) | Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze | |
| JPH0672103B2 (ja) | 慢性関節リウマチ性貧血治療剤 | |
| DE4311651A1 (de) | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen | |
| EP0809700A1 (de) | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung | |
| DE60009529T2 (de) | Pharmazeutische zusammensetzung aus fibrinolytischem mittel | |
| EP2558116B2 (de) | Mittel zur lokalen behandlung von zervixdysplasien | |
| DE69101784T2 (de) | Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor. | |
| DE69434564T2 (de) | Pharmazeutische zusammensetzungen und deren verwendung insbesondere in der behandlung von neurodegenerativen krankheiten | |
| Rweyemamu et al. | Observations on the histopathology of bovine herpes mammillitis | |
| DE19526174C2 (de) | Mittel gegen Tumorwachstum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |